<DOC>
	<DOCNO>NCT00151047</DOCNO>
	<brief_summary>Purpose : The purpose clinical trial look chemotherapy combination docetaxel capecitabine treatment newly diagnose locally advanced prostate cancer , determine treatment acceptable , effective safe treatment option . In addition , clinical trial evaluate treatment affect chemical ( enzyme ) , cancer relate genetic change tumor . Optional : This clinical trial conduct extra image study research purpose include combine endorectal prostate magnetic resonance imaging ( MRI ) , magnetic resonance spectroscopy ( MRSI ) diffusion weight imaging ( DWI ) evaluate prostate cancer response study treatment .</brief_summary>
	<brief_title>Docetaxel Plus Capecitabine Newly Diagnosed Localized Locally Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients must newly diagnose prostate cancer least one follow criterion : Clinical Stage &gt; T2 PSA &gt; 15 ng/ml Biopsy Gleason 's sum &gt; 8 All patient must minimum PSA value &gt; 5 ng/ml . Patients may evidence distant systemic metastasis . Patients may undergo concurrent hormonal , biologic , chemotherapy . Patients may prior unanticipated severe reaction fluoropyrimidine therapy know hypersensitivity 5fluorouracil . Patients history severe reaction docetaxel drug formulate polysorbate 80 eligible . Patients may underlie cardiac disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>